Objective: To examine the role of MAGEA2 in the tumorigenesis of head and neck squamous cell carcinoma (HNSCC).
I
N 2008, MORE THAN 47 500 NEW casesofcanceraffectingtheoralcavity, pharynx, and larynx were diagnosed in the United States, resulting in more than 11 000 deaths. More than 90% of these cancers were squamous cell in origin, and, worldwide, more than 500 000 people have head and neck squamous cell carcinoma (HNSCC). 1, 2 Despite recent advances in the surgical and radiotherapeuticmanagementofthesepatients, 5-year survival rates for HNSCC have only moderately improved secondary to most tumors being diagnosed at late clinical stages andthesetumorshavingarelativelyhighrate of locoregional recurrence. The discovery of differentiallyexpressedmoleculartargetsfollowed by research aimed at improving our understanding of their function and expression patterns is a promising approach to increase our ability to detect cancer at an early or premalignant stage and to aid in the development of targeted therapeutics and advanced surveillance methods.
Epigenetic changes, including alterations in promoter methylation, have been associated with cancer-specific expression differences in human malignancies, including HNSCC. [3] [4] [5] [6] [7] We recently developed an integrative epigenetic screening method, combining primary tissue messenger RNA expression array data with that from pharmacologically demethylated immortalized normal oral keratinocytes. This research represents the first comprehensive approach to identify proto-oncogenes activated by promoter demethylation in HNSCC. One of the putative derepressed oncogenes discovered via this screening method was MAGEA2. 7 The MAGEA family of genes is a member of the cancer-testis antigens gene family. These genes were first discovered as immunogenic targets normally expressed in germline cells but differentially expressed in a variety of human cancers. Although this family of genes has been shown to be overexpressed in melanoma and other cancers, to date, efforts have primarily focused on developing tumor vaccines based on these targets, leaving their function mostly a mystery. [8] [9] [10] [11] In addition to a recent study 7 showing that MAGEA2 expression in HNSCC is regulated by promoter demethylation, there has been recent compelling evidence that MAGEA2 silences the downstream targets of p53 activation via the MAGEA2-p53 complex in melanoma. 12 Genetic alterations in the powerful tumor suppressor TP53 are found in approximately 50% of HNSCC. Although TP53 has a long and established role in the pathogenesis of head and neck cancer, many primary HNSCC tumors have been shown to lack mutations in the TP53 tumor suppressor gene, and it is recognized that other mechanisms of functional inactivation must exist. 13, 14 In this study, we examine the role of MAGEA2 in the tumorigenesis of HNSCC. We confirm that MAGEA2 is differentially overexpressed in HNSCC; in addition, we show that MAGEA2 is growth promoting, in part, through its interaction with the p53 pathway by increasing cellular proliferation and decreasing cell cycle arrest.
METHODS

HISTOPATHOLOGIC ANALYSIS
All the samples were analyzed at the Department of Pathology, The Johns Hopkins Hospital. Tissue samples were obtained via Johns Hopkins institutional review boardapproved protocols. Tumor and normal tissues from surgical specimens were frozen in liquid nitrogen immediately after resection and stored at −80°C until use. Normal samples were microdissected, and RNA was prepared from the mucosa. Tumor samples were confirmed to be HNSCC and subsequently were microdissected to separate tumor from stromal elements to yield at least 80% tumor cells; tissue RNA was then extracted as described in the following subsection.
ISOLATION OF RNA AND QUANTITATIVE REVERSE TRANSCRIPTION-POLYMERASE CHAIN REACTION
Total cellular RNA was isolated using TRIzol (Life Technologies, Gaithersburg, Maryland) and the RNeasy Kit (Qiagen,Valencia, California) according to the manufacturer's instructions for primary tissue and cell line samples. After measuring the concentration of the RNA extracted from each sample, 1 µg RNA was then used for complementary DNA synthesis performed using oligo-dt and the SuperScript First-Strand Synthesis Kit (Invitrogen, Carlsbad, California ). All the primers were designed to span exon-exon junctions to avoid cross-reactivity to DNA. 18s ribosomal RNA was used as the internal control gene, and all values were normalized to 18s ribosomal RNA expression. Each experiment was performed in triplicate using the TAqMan 7900 (Applied Biosystems, Foster City, California) real-time PCR machine and the QuantiFast SYBR Green PCR Kit (Qiagen) according to the manufacturer's instructions. Detailed PCR conditions and primer sequences are available on request.
PUBLIC DATA SETS
The public databases used in this study were the University of California, Santa Cruz Human Genome reference sequence and the annotation database from the March 2006 freeze (hg18). Fortynine HNSCC tumor and 19 normal upper aerodigestive tissue expression microarrays were obtained from public data sets using Oncomine (Compendia Bioscience, Ann Arbor, Michigan). All the expression arrays used for this analysis had been performed using the Affymetrix Human Genome U133A Array expression platform (Affymetrix, Inc, Santa Clara, California). 
CANCER OUTLIER PROFILE ANALYSIS
SMALL-INTERFERING RNA TRANSFECTIONS
Small-interfering RNAs (siRNAs) for MAGEA2 knockdown were purchased from Dharmacon (Chicago, Illinois), as were nonsilencing control scramble siRNAs. Transfection was accomplished using the Lipofectamine 2000 transfection reagent per the manufacturer's protocol (Invitrogen). Briefly, siRNA constructs were transiently transfected into JHU-O11 cells at a final concentration of 5 pmol. Scramble siRNAs were transfected in the same manner at the same concentration. All transfection experiments were performed in triplicate.
CELL CYCLE ANALYSIS
For cell cycle analysis, cells were plated in 100-mm dishes. For contact inhibition, transfected cells were allowed to reach confluence and to remain confluent for at least 48 hours as previously described. 16 At 48 hours, cells were trypsinized, centrifuged, and fixed with methanol. Cells were then resuspended in 0.1 mg/mL of propidium iodide. DNA content was measured using flow cytometry analysis performed using a FACScan flow cytometer (BD, Franklin Lakes, New Jersey) by analyzing 10 000 events. All gating for the controls and samples was identical. 
RESULTS
MAGEA2 IS DIFFERENTIALLY OVEREXPRESSED IN HNSCC PRIMARY TISSUE
A previous work 7 demonstrated that MAGEA2 can be derepressed by pharmacologic demethylation of normal oral keratinocyte cells. In this study, we initially examined the expression of MAGEA2 in primary HNSCC compared with noncancer normal upper aerodigestive mucosal control tissue. We first obtained HNSCC tumor and normal tissue messenger RNA expression arrays from the Oncomine database that had been performed on the Affymetrix Human Genome U133A Array expression platform. We used the score generated by COPA at the 90th percentile of tumor vs normal expression after specific normalization to rank candidate oncogenes in these 49 HNSCC tumors and 19 normal upper aerodigestive tissues.
15 Figure 1 shows the COPA expression results for MAGEA2. There was a significant difference using the Mann-Whitney test (P Ͻ .001), with 15 of 49 tumors (31%) showing significant upregulation of MAGEA2.
To confirm these microarray results, we performed qRT-PCR on a separate cohort of HNSCC and normal, noncancer upper aerodigestive mucosal samples. We found significant overexpression of MAGEA2 in 32 tumors compared with 7 normal tissues (P=.03) (Figure 2) .
In addition, we examined whether MAGEA2 overexpression was more common in the HNSCC tumors that had wild-type p53. To this end, we conducted a subset analysis of 21 of the 32 tumors for which the p53 status was known. Of the 15 tumors with mutant p53, the mean (SD) relative MAGEA2 messenger RNA expression level by means of qRT-PCR was 0.006174434 (0.0094). Of the 6 tumors with wild-type p53, the mean (SD) relative MAGEA2 messenger RNA expression level was 0.034628791 (0.0394). Although there is a difference, with MAGEA2 expression being higher in tumors expressing wild-type p53, P=.14 using a 2-tailed t test assuming unequal variance, this difference did not reach significance.
MAGEA2 PROVIDES A SELECTIVE GROWTH ADVANTAGE IN HNSCC AND NORMAL ORAL KERATINOCYTE CELL LINES
Given the finding that MAGEA2 is differentially overexpressed in HNSCC, we next turned our attention toward elucidating its function in these tumors. Transient transfection of an MAGEA2 construct into a spontaneously immortalized oral keratinocyte cell line, NOK-SI, 17 showed a mean (SD) 34% (3%) increase in AD growth at 72 hours ( Figure 3A and Figure 4A ). We then used siRNA to knock down MAGEA2 expression in an HNSCC cell line, JHU-O11, shown to be a high expresser of MAGEA2. Seventy-two hours after the introduction of MAGEA2 siRNA, there was a mean (SD) 28% (3%) decrease in AD growth compared with the cells treated with nonspecific scramble control siRNA ( Figure 3B and Figure 4B ). Transient transfection of MAGEA2 was unable to transform either NIH-3T3 or OKF6-Tert-1 cell lines to grow anchorage independently in soft agar (data not shown).
MAGEA2 DOWNREGULATES p53 TARGETS IN NORMAL HUMAN ORAL KERATINOCYTE AND MOUSE FIBROBLAST CELL LINES
Given the recent evidence that MAGEA2 interacts with p53 in melanoma cells, we wanted to examine whether MAGEA2 causes expression differences in downstream targets of p53 in normal oral keratinocytes and mouse fibroblasts. 12 We used qRT-PCR to determine whether transient transfection of MAGEA2 alters the expression levels of 2 main downstream targets of the p53 tumor suppressor gene, BAX and CDKN1A. Both CDKN1A and BAX were significantly downregulated in normal human oral keratinocyte cells, OKF6-Tert-1 (P=.03) (Figure 5A) . 18 In another normal oral keratinocyte cell line, NOK-SI, CDKN1A (P=.01) and BAX (P=.04) were significantly downregulated after MAGEA2 transfection, although CDKN1A was downregulated to a higher degree ( Figure 5B ). In NIH-3T3 cells, CDKN1A was significantly downregulated (P=.01), whereas BAX was downregulated but is not significant ( Figure 5C ).
MAGEA2 SELECTIVELY INCREASES GROWTH IN THE p53 WT HCT116 CELL LINE
To further understand whether MAGEA2 exerts its growth effects via the p53 pathway, we transiently transfected a MAGEA2 construct into the well-studied colon carcinoma HCT116 p53 wt (ϩ/ϩ) and p53 null (−/−) cell line system. 19 Figure 6A shows a baseline increase in AD growth in the p53 null cell line over the wild-type cell line, which was overcome by transient transfection of MAGEA2 into the wt p53 cell line. Seventy-two hours after transfection of MAGEA2 into the p53 wt HCT116ϩ/ϩ cells, we observed a mean (SD) 30% (10%) increase in AD growth ( Figure 6B ). However, no growth advantage was seen with the transfection of MAGEA2 into the HCT116 p53 null (−/−) cells ( Figure 6C ).
MAGEA2 PREVENTS G1 ARREST IN NORMAL ORAL KERATINOCYTES
We next examined whether MAGEA2, through its effect on p53, exerts its growth effects in normal oral keratinocytes by decreasing cell cycle arrest or by downregulating the apoptotic pathway. After transient transfection with an MAGEA2 construct, we arrested NOK-SI cells in culture by allowing the cells to remain confluent for more than 48 hours. The cells were then stained with propidium iodide, and cell cycle analysis was conducted using flow cytometry to analyze cellular DNA content.
The analysis showed that NOK-SI cells transfected with MAGEA2 had a significantly smaller percentage of cells arrested in G1 (67%), compared with cells transfected with the empty vector (80%) in G1 arrest (P = .047) (Figure 7) . After release from confluent conditions, by 9 hours, NOK-SI cells transfected with the empty vector or MAGEA2 had returned to a similar distribution of cells in G1, S, and G2 (data not shown). In addition, apoptosis assays conducted with and without MAGEA2 transfection in OKF6-Tert-1 and NIH-3T3 cells after treatment with a DNA-damaging agent, camptothecin, revealed no difference in cells undergoing apoptosis.
COMMENT
The search for tumor-specific antigens has been active for many decades, with the discovery of the first MAGEA family member occurring almost 20 years ago. Yet, the function of the MAGEA family of genes has remained unclear. 10, 20, 21 Although this family of genes has been shown to be overexpressed in a variety of human tumors affecting the skin, breasts, gastrointestinal tract, lungs, liver, and head and neck, efforts have mainly focused on developing tumor vaccines based on these targets. [22] [23] [24] [25] [26] [27] [28] Only in recent years have members of the MAGEA family been implicated in various tumorigenic pathways. For example, MAGEA1 has been implicated as a transcriptional repressor through its interaction with SKI-interacting protein and recruitment of histone deacetylase in the NOTCH1 pathway. 29 In addition, MAGEA11 has been shown to inhibit the hypoxia-inducible factor prolyl hydroxylase 2 and to activate the hypoxic response in various cancer cell lines. MAGEA11 has also been shown to interact with and regulate androgen receptor function. 30, 31 So far, one study 12 has elucidated the interaction between MAGEA2 and the p53 pathway in melanoma; however, to date, there has been no study, to our knowledge, looking specifically at the expression pattern and function of MAGEA2 in HNSCC.
In this study, we used the bioinformatics approach COPA to analyze primary tissue expression microarrays obtained from public data sets available on Oncomine to determine that MAGEA2 is differentially overexpressed in primary HNSCC vs normal upper aerodigestive tract mucosa. COPA is a method used to search for marked overexpression of particular genes that occur in a subset of patients. Traditional analytical methods based on standard statistical measures often do not find genes with this type of expression profile. 15 COPA was useful to search for and analyze MAGEA2 expression in primary tissue because it is known that cancer-testis antigens are heterogeneously expressed across a wide patient population and in individual tumor specimens. 32, 33 We then confirmed this overexpression by means of qRT-PCR in a separate cohort of 32 primary tissues and 7 normal upper aerodigestive mucosal samples from patients without cancer and again found statistically significant over- We also attempted to demonstrate that MAGEA2 is overexpressed more frequently in tumors that contain wild-type p53. Although the data showed a trend in this direction, the small sample size precluded significance.
Recently, Monte et al 12 showed that the MAGEA2 protein induces a novel p53 inhibitory loop involving recruitment of histone deacetylase 3 (HDAC3) to a MAGEA2-p53 complex. This complex formation strongly downregulates the p53 transactivation function in melanoma without changing p53 expression levels. 12 Given these findings and data suggesting that TP53 mutations in HNSCC are common but do not account for all of the dysfunction in the p53 pathway, we examined the effect of MAGEA2 on downstream targets and pathways of p53 involved in cell cycle progression and apoptosis. 13, 14, 34, 35 We initially showed that transient transfection of MAGEA2 into normal oral keratinocytes could increase cell proliferation and that knockdown of this gene using siRNA could decrease AD growth in HNSCC cells known to be high expressers of MAGEA2 (the JHU-O11 cell line). In addition, transfection of MAGEA2 into the well-studied HCT116 p53 wt (ϩ/ϩ) and p53 null (−/−) cell line system only increased AD growth in the p53 wt clone. Thus, MAGEA2 was able to elicit only a selective growth advantage in the cell line with intact p53. Based on these findings and the current understanding of the interaction between MAGEA2 and p53, we next examined the effect of MAGEA2 expression on the downstream targets of the p53 pathway.
Silencing of the tumor suppressor gene TP53 and its downstream targets has the ability to decrease the rate of apoptosis or increase the rate of cellular proliferation by deregulating cell cycle progression checkpoints. 34, 35 To examine which scenario was occurring in the present transfected cell lines, we first examined 2 targets of p53, CDKN1A and BAX. The former is responsible for cell cycle regulation at the G1 checkpoint, and the latter is responsible for p53-induced apoptosis. [36] [37] [38] In all the cell lines tested, there was a significant decrease in CDKN1A and BAX expression after transient transfection with MAGEA2. In 2 of the 3 cell lines, NIH-3T3 and NOK-SI, there was a higher degree of CDKN1A silencing compared with the downregulation of BAX after MAGEA2 transfection ( Figure 5 ).
To examine the functional significance of these findings, we performed apoptotic and cell cycle progression analyses to determine whether either were affected by MAGEA2 expression. We found no difference in apoptosis after DNA damage in any of the tested cell lines; however, in the normal oral keratinocyte cell line (NOK-SI) transfected with MAGEA2, there was a significant decrease in cell cycle arrest after 48 hours of culturing in confluent conditions compared with the empty vector controls. These findings support that MAGEA2 is growth promoting in models of HNSCC, at least in part, through its interaction with the cell cycle progression arm of the p53 pathway.
Epigenetic changes have been implicated in the pathogenesis of solid tumors, including HNSCC. A previous work 7 implicated promoter hypomethylation as a major contributor to the derepression of MAGEA2 in HNSCC. In this study, we showed that MAGEA2 is overexpressed in a significant subset of HNSCCs. In addition, we showed that MAGEA2 overexpression results in increased cell cycle progression and increased growth, in part by inhibiting the activation of p53 downstream targets in normal oral keratinocytes and HNSCC cell lines.
The lack of expression of the MAGEA family of genes in adult tissue and their widespread expression across various human malignancies make them ideal targets for diagnostic approaches and therapeutic interventions. However, we must continue to strive to improve our understanding of the pathways involved in the tumorigenic effects of MAGEA2 and other cancer-testis antigen family members to allow us to better tailor these therapeutics and drug combinations to most effectively halt disease progression. 
